NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma NAMS, revealing diverse outlooks from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.2, along with a high estimate of $37.00 and a low estimate of $31.00. Surpassing the previous average price target of $35.00, the current average has increased by 0.57%.

Investigating Analyst Ratings: An Elaborate Study

The standing of NewAmsterdam Pharma among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NewAmsterdam Pharma. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for NewAmsterdam Pharma's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

For valuable insights into NewAmsterdam Pharma's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on NewAmsterdam Pharma analyst ratings.

Unveiling the Story Behind NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Breaking Down NewAmsterdam Pharma's Financial Performance

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: NewAmsterdam Pharma displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 889.83%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: NewAmsterdam Pharma's net margin excels beyond industry benchmarks, reaching -57.18%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): NewAmsterdam Pharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -4.34%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): NewAmsterdam Pharma's ROA stands out, surpassing industry averages. With an impressive ROA of -3.76%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.

The Significance of Analyst Ratings Explained

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.